Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Scot Wolfe PhD

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Wolfe, Scot

PropertyValue
Rotation Projects

Potential Rotation Projects

Improving the Precision of CRISPR/Cas9 nucleases for gene therapy applications:

We are working to improve the precision of the CRISPR/Cas9 system to generate nucleases that will cleave at only a single site in the genome.  These engineering efforts focus on increasing the DNA-editing precision of Cas9 and using protein engineering to introduce new properties into the nuclease.  Much of this work is now transitioning to the use of Cas9 (and Cas12a) protein-RNA complexes.  These modified nucleases will then be applied to patient derived cell-culture systems for the targeted repair or inactivation of disease-causing alleles.  With the eventual goal of creating therapeutics for Sickle Cell Disease, beta-Thalassemia, HIV, Limb Girdle Muscular Dystrophy, Hermansky Pudlak Syndrome and other monogenic disorders.

ex vivo genome editing in CD34+ HSPCs:

We are developing improved Cas9 proteins for delivery ex vivo into CD34+ HSPCs for therapeutic application to sickle cell disease and beta-thalassemia. The goal is to modify the hematopoietic stem cells of a patient to complement the loss of function of the beta-globin gene and then return these cells to the patient through an autologous transplant. 

Development of Cys2His2 Zinc fingers proteins (ZFPs) as targeted therapeutics:

We are developing artificial ZFPs for the regulation of target genes to change their gene expression profiles for therapeutic applications.

 


One or more keywords matched the following items that are connected to Wolfe, Scot


Search Criteria
  • Globins